RESUMEN
OBJECTIVE: The aim: To investigate the effectiveness of complex protocol treatment with the additional inclusion of a course of the sublingual form of hepatoprotector on the clinical manifestations of patients with chronic pancreatitis in combination with type 2 diabetes mellitus. PATIENTS AND METHODS: Materials and methods: We studied 57 outpatients with chronic pancreatitis in the phase of stable or unstable remission in combination with diabetes mellitus in the phase of stable or unstable remission. Two groups were formed according to randomization principles to study the effectiveness of the proposed correction programs: 1stgroup (30 patients) took protocol treatment for one month, 2nd group (27 patients) - received protocol treatment with a course of hepatoprotector. RESULTS: Results: It was found the results of the impact of two treatment programs on some clinical symptoms and syndromes in patients with chronic pancreatitis. Positive dynamics of clinical symptoms/syndromes were found in both groups of patients, but the therapeutic effect in the 2nd group was more significant. Analysis of the dynamics of the Quality of Life parameters on the scales of a specialized gastroenterological questionnaire under the influence of two treatment programs found statistically significant (p<0.05) changes in the group with the inclusion of hepatoprotector for treatment for all parameters in contrast to the group of protocol treatment, where statistically significant changes on three scales (abdominal pain, gastric reflux, and dyspepsia). CONCLUSION: Conclusions: It is proved that the proposed inclusion in the protocol treatment of a combination of CP and DM2 course of sublingual a demethion in eledtoan increase in its effectiveness in the correction of abdominal pain - by 8.2%, dyspepsia - by 17.8%, constipation - by 7.4% , diarrhea - by 12.9%, astheno-neurotic - by 21.5%, allergic - by 15.9%, autonomic - by 20.1% (p<0.05). Found higher efficacy of treatment with the in clusion of a demethion in relation to that in the group of PL on the dynamics of the parameters of the scales of the GSRS questionnaire by a total of 13.7%, p <0.01: abdominal pain decreased by 22.6% vs. 16.7%, gastricreflux - by 34.7% against 16.9% (p <0.05), diarrhea - by 23.9% against 8.2% (p<0.001), constipation - by 20.6% against 5.9% (0.01), dyspepsia - by 32.4% against 17.9% (p <0.01), respectively. It proved the feasibility of using sublingual demethion in the complex rehabilitation treatment of patients with comorbidity of CP and diabetes mellitus in order to correct clinical symptoms.
Asunto(s)
Diabetes Mellitus Tipo 2 , Dispepsia , Pancreatitis Crónica , Dolor Abdominal/tratamiento farmacológico , Dolor Abdominal/etiología , Comorbilidad , Estreñimiento , Diabetes Mellitus Tipo 2/complicaciones , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diarrea , Humanos , Pancreatitis Crónica/complicaciones , Pancreatitis Crónica/tratamiento farmacológico , Calidad de Vida , SíndromeRESUMEN
OBJECTIVE: The aim: To assess the state of typical pathogenetic syndromes (inflammation, endotoxicosis, liperoxidation, enzymatic and non-enzymatic antioxidant deficiency) in the comorbidity of type 2 diabetes mellitus (DM2) and chronic pancreatitis (CP). PATIENTS AND METHODS: Materials and methods: We examined 137 patients (112 patients with comorbidity of CP and DM2 and 25 patients with isolated CP. Typical pathogenetic syndromes (inflammation, endotoxicosis, liperoxidation, enzymatic and non-enzymatic antioxidant deficiency) were determined. RESULTS: Results: It was proved that patients with CP even in the remission phase of the active course of EI and LPO, which was significantly more significant in comorbidity with DM2. Statistically significant more significant changes in the parameters of antioxidant protection in the comorbidity of CP and DM2 in relation to those in isolated CP. CONCLUSION: Conclusions: Treatment of CP and DM2 is a difficult task and should take into account the impact on the studied common typical pathogenetic syndromes - inflammation, endotoxicosis, lipid peroxidation, and enzyme and non-enzymatic antioxidant protection - to address short-term and prevent long-term complications.
Asunto(s)
Diabetes Mellitus Tipo 2 , Pancreatitis Crónica , Comorbilidad , Diabetes Mellitus Tipo 2/epidemiología , Humanos , Inflamación , Pancreatitis Crónica/epidemiología , SíndromeRESUMEN
OBJECTIVE: The aim: Make complex study of bone density in patients with primary osteoarthritis and exocrine pancreatic insufficiency and patients with primary osteoarthritis without exocrine pancreatic insufficiency. PATIENTS AND METHODS: Materials and methods: There were examined 140 patients with primary osteoarthritis without exocrine pancreatic insufficiency and combination osteoarthritis and exocrine pancreatic insufficiency. Diagnosis of osteoarthritis was based on diagnostic X-Ray criteria - according to J.H. Kellgren and J.S. Lawrence. The level of exocrine pancreatic insufficiency was based on result of Elisa test. State of mineral bone density was examined by using dual-photon densitometry. RESULTS: Results: It was established that there was a progressive, statistical, significant increase of mineral density of bone tissue in the 1-st group patients with osteoarthritis. Patients in the 2-nd group, with osteoarthritis in the comorbidity with exocrine pancreatic insufficiency, the densitogram rates were statistically significantly lower than in patients in the 1-st group. CONCLUSION: Conclusions: The changes of bone tissue can be explained by the formation of trophological insufficiency as a result of exocrine pancreatic insufficiency. One of the symptoms of trophic failure is bone and mineral changes, in particular, the decrease of bone density.